Takeda says Phase 3 zasocitinib pill clears plaque psoriasis skin in about 70% patients

Reuters03-30

Takeda says Phase 3 zasocitinib pill clears plaque psoriasis skin in about 70% patients

Takeda disclosed new Phase 3 data for investigational oral TYK2 inhibitor zasocitinib (TAK-279) in moderate-to-severe plaque psoriasis, already presented March 28 at 2026 American Academy of Dermatology Annual Meeting.
Latitude PsO 3001 and 3002 showed about 70% of patients achieved sPGA 0/1 at week 16, versus about 11%–13% on placebo.
Week 16 PASI 90 reached 61.3% in one study, 51.9% in other study, versus 5% or less on placebo.
Latitude PsO 3002 showed PASI 75 at week 4 of 16.8%, versus 4.3% on placebo.
Takeda targets New Drug Application submissions starting in fiscal 2026, with expected psoriasis launch timing shown as 2027 H1 pending regulatory review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: FUO8M3WJPA1OR96Z) on March 30, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623315937?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 17:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623315937","market":"fut","top_or_hot":-1,"title":"Takeda says Phase 3 zasocitinib pill clears plaque psoriasis skin in about 70% patients","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Takeda says Phase 3 zasocitinib pill clears plaque psoriasis skin in about 70% patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Takeda disclosed new Phase 3 data for investigational oral TYK2 inhibitor zasocitinib (TAK-279) in moderate-to-severe plaque psoriasis, already presented March 28 at 2026 American Academy of Dermatology Annual Meeting.\n        </li>\n<li>\n          Latitude PsO 3001 and 3002 showed about 70% of patients achieved sPGA 0/1 at week 16, versus about 11%–13% on placebo.\n        </li>\n<li>\n          Week 16 PASI 90 reached 61.3% in one study, 51.9% in other study, versus 5% or less on placebo.\n        </li>\n<li>\n          Latitude PsO 3002 showed PASI 75 at week 4 of 16.8%, versus 4.3% on placebo.\n        </li>\n<li>\n          Takeda targets New Drug Application submissions starting in fiscal 2026, with expected psoriasis launch timing shown as 2027 H1 pending regulatory review.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief via <a href=\"https://laohu8.com/S/SPXCF\">Singapore Exchange</a> Limited (SGX) (Ref. ID: FUO8M3WJPA1OR96Z) on March 30, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Takeda says Phase 3 zasocitinib pill clears plaque psoriasis skin in about 70% patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTakeda says Phase 3 zasocitinib pill clears plaque psoriasis skin in about 70% patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-30 17:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Takeda says Phase 3 zasocitinib pill clears plaque psoriasis skin in about 70% patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Takeda disclosed new Phase 3 data for investigational oral TYK2 inhibitor zasocitinib (TAK-279) in moderate-to-severe plaque psoriasis, already presented March 28 at 2026 American Academy of Dermatology Annual Meeting.\n        </li>\n<li>\n          Latitude PsO 3001 and 3002 showed about 70% of patients achieved sPGA 0/1 at week 16, versus about 11%–13% on placebo.\n        </li>\n<li>\n          Week 16 PASI 90 reached 61.3% in one study, 51.9% in other study, versus 5% or less on placebo.\n        </li>\n<li>\n          Latitude PsO 3002 showed PASI 75 at week 4 of 16.8%, versus 4.3% on placebo.\n        </li>\n<li>\n          Takeda targets New Drug Application submissions starting in fiscal 2026, with expected psoriasis launch timing shown as 2027 H1 pending regulatory review.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief via <a href=\"https://laohu8.com/S/SPXCF\">Singapore Exchange</a> Limited (SGX) (Ref. ID: FUO8M3WJPA1OR96Z) on March 30, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0831103253.SGD","symbol_name":"JPMorgan Funds - Asia Pacific Income A (mth) SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDLH55cq:1","article_id":"2623315937","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623315937","pubTimestamp":1774864634,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Takeda disclosed new Phase 3 data for investigational oral TYK2 inhibitor zasocitinib  in moderate-to-severe plaque psoriasis, already presented March 28 at 2026 American Academy of Dermatology Annual Meeting.Latitude PsO 3001 and 3002 showed about 70% of patients achieved sPGA 0/1 at week 16, versus about 11%–13% on placebo.Week 16 PASI 90 reached 61.3% in one study, 51.9% in other study, versus 5% or less on placebo.Latitude PsO 3002 showed PASI 75 at week 4 of 16.8%, versus 4.3% on placebo.Takeda targets New Drug Application submissions starting in fiscal 2026, with expected psoriasis launch timing shown as 2027 H1 pending regulatory review.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0831103253.SGD":"JPMorgan Funds - Asia Pacific Income A (mth) SGD","SG9999004360.SGD":"Nikko AM Shenton Thrift Fund SGD","LU0877626530.USD":"FIDELITY ASIA PACIFIC DIVIDEND \"A\" (USD) INC MONTHLY (G)","SG9999001846.SGD":"Schroder Asian Equity Yield A Dis SGD","SGXZ27511609.SGD":"NIKKO AM SINGAPORE DIVIDEND EQUITY \"SGD\" (SGD) ACC","LU1119993845.HKD":"FIDELITY ASIA PACIFIC DIVIDEND \"A\" (HKDHDG) INC","SG9999003826.SGD":"日兴资管新加坡股息基金 SGD","BK6033":"金融交易所和数据","LU0326948709.USD":"SCHRODER ISF ASIAN TOTAL RETURN \"A\" (USD) ACC","SG9999013460.SGD":"LionGlobal Singapore Dividend Equity Fund SGD","SG9999013486.USD":"LIONGLOBAL SINGAPORE DIVIDEND EQUITY (USD) INC A","LU2242646235.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) ACC","LU0441851309.USD":"JPM ASEAN EQUITY \"A\" ACC","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","SG9999013478.USD":"利安新加坡股息基金","LU0188438112.USD":"SCHRODER ISF ASIAN EQUITY YIELD \"A\" ACC","SG9999000343.SGD":"Schroder Singapore Trust A Dis SGD","SGXZ58947870.SGD":"LIONGLOBAL SINGAPORE DIVIDEND EQUITY (SGDHDG) INC","SG9999006266.SGD":"MANULIFE SINGAPORE EQUITY \"A\" (SGD) ACC","LU1920063259.USD":"FIDELITY FUNDS GLOBAL DIVIDEND PLUS \"A\" (USDHDG) INC","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU2401740654.USD":"FIDELITY SUSTAINABLE GLOBAL DIVIDEND PLUS \"A\" (USD) INC","LU1920062954.HKD":"FIDELITY FUNDS GLOBAL DIVIDEND PLUS \"A\" (HKDHDG) INC","LU0898667661.SGD":"JPMorgan Funds - Asia Pacific Income A (mth) SGD-H","BK6516":"银行与投资服务概念","LU0532188223.SGD":"JPMorgan Funds - ASEAN Equity A (acc) SGD","SG9999001135.SGD":"United ASEAN Fund SGD","SG9999016042.SGD":"Schroder Singapore Trust A Acc SGD","LU0192582467.USD":"SCHRODER ISF ASIAN EQUITY YIELD \"A\" (USD) INC MF","LU0205439572.USD":"富达亚太股息基金","TAK":"武田制药","BK6523":"ESG概念","LU1839390173.USD":"JPM ASEAN EQUITY \"A\" (USD) INC","SG9999014492.USD":"NIKKO AM ASEAN EQUITY \"A\" (USD) ACC","IE00BKZH1Z71.USD":"BNY MELLON ASIAN INCOME \"B\" (USD) ACC","SG9999014484.SGD":"Nikko AM ASEAN Equity Fund A SGD"},"translate_title":"武田称3期zasocitinib药丸可清除约70%患者的斑块型银屑病皮肤","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TAK":1.95},"content_text":"Takeda says Phase 3 zasocitinib pill clears plaque psoriasis skin in about 70% patients\n    \n\n\n          Takeda disclosed new Phase 3 data for investigational oral TYK2 inhibitor zasocitinib (TAK-279) in moderate-to-severe plaque psoriasis, already presented March 28 at 2026 American Academy of Dermatology Annual Meeting.\n        \n\n          Latitude PsO 3001 and 3002 showed about 70% of patients achieved sPGA 0/1 at week 16, versus about 11%–13% on placebo.\n        \n\n          Week 16 PASI 90 reached 61.3% in one study, 51.9% in other study, versus 5% or less on placebo.\n        \n\n          Latitude PsO 3002 showed PASI 75 at week 4 of 16.8%, versus 4.3% on placebo.\n        \n\n          Takeda targets New Drug Application submissions starting in fiscal 2026, with expected psoriasis launch timing shown as 2027 H1 pending regulatory review.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: FUO8M3WJPA1OR96Z) on March 30, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623315937","isCrawlerRequest":true}